Home/Pipeline/PROSTest®

PROSTest®

Prostate Cancer

CommercialActive

Key Facts

Indication

Prostate Cancer

Phase

Commercial

Status

Active

Company

Wren Laboratories

About Wren Laboratories

Wren Laboratories is a pioneering diagnostics company specializing in mRNA-based liquid biopsy for oncology. Its core innovation is a proprietary RNA stabilization and testing platform that profiles multi-gene mRNA expression to detect active signaling pathways in tumors, offering insights for personalized cancer management and drug development. The company has launched two clinically validated tests, NETest® for neuroendocrine tumors and PROSTest® for prostate cancer, and is supported by an extensive intellectual property portfolio and numerous peer-reviewed publications. It operates as a certified laboratory service provider, serving both clinicians and biopharma partners.

View full company profile

Therapeutic Areas

Oncology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active